These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30883325)

  • 1. Assessing the Legal and Practical Implications of Copay Accumulator and Maximizer Programs.
    Linehan JS
    Manag Care; 2019 Feb; 28(2):42-44. PubMed ID: 30883325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
    Starner CI; Alexander GC; Bowen K; Qiu Y; Wickersham PJ; Gleason PP
    Health Aff (Millwood); 2014 Oct; 33(10):1761-9. PubMed ID: 25288420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Insurers Often Foot Bill When Drug Coupons Are Used.
    Wolinsky H
    Manag Care; 2017 Mar; 26(3):38-39. PubMed ID: 28510519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost.
    Fendrick AM; Smith DG; Chernew ME; Shah SN
    Am J Manag Care; 2001 Sep; 7(9):861-7. PubMed ID: 11570020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Insurer Strategies to Reduce Specialty Drug Spending-Copayment Adjustment and Alternative Funding Programs.
    Zuckerman AD; Schneider MP; Dusetzina SB
    JAMA Intern Med; 2023 Jul; 183(7):635-636. PubMed ID: 37252717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rubik's Cube of Manufacturers' Coupons: Making the Case for Sneetches.
    Wolf B
    HCA Healthc J Med; 2023; 4(2):87-89. PubMed ID: 37424988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient perceptions of copay card utilization and policies.
    Cavalier D; Doherty B; Geonnotti G; Patel A; Peters W; Zona S; Shea L
    J Mark Access Health Policy; 2023; 11(1):2254586. PubMed ID: 37692554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copayments Not Counting Toward the Deductible Could Have Unintended Consequences.
    Schafer J; Gopalan A
    Manag Care; 2017 Dec; 26(12):34-35. PubMed ID: 29272243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value-based insurance design: quality improvement but no cost savings.
    Lee JL; Maciejewski M; Raju S; Shrank WH; Choudhry NK
    Health Aff (Millwood); 2013 Jul; 32(7):1251-7. PubMed ID: 23836741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAAP rule and prescription drug prices.
    Walsh BS; Kesselheim AS
    Am J Manag Care; 2021 Aug; 27(8):312-314. PubMed ID: 34460172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Episode-Based Cost Sharing to Prospectively Guarantee Patients' Out-of-Pocket Costs.
    Horný M; Anderson DM; Fendrick AM
    JAMA Intern Med; 2024 Jun; 184(6):597-598. PubMed ID: 38466297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study.
    Daubresse M; Andersen M; Riggs KR; Alexander GC
    Pharmacotherapy; 2017 Jan; 37(1):12-24. PubMed ID: 27455456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health plans' strategies to control prescription drug spending.
    Wallack SS; Weinberg DB; Thomas CP
    Health Aff (Millwood); 2004; 23(6):141-8. PubMed ID: 15537592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.
    Lurk JT; DeJong DJ; Woods TM; Knell ME; Carroll CA
    Am J Health Syst Pharm; 2004 Feb; 61(3):267-72. PubMed ID: 14986557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Will the Affordable Care Act's Cost-Sharing Reductions Affect Consumers' Out-of-Pocket Costs in 2016?
    Collins SR; Gunja M; Beutel S
    Issue Brief (Commonw Fund); 2016 Mar; 6():1-17. PubMed ID: 27017638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Out-of-pocket payments in arthritis: spur to prudent purchasing or red herring?
    Yelin E
    Arthritis Rheum; 2008 Aug; 58(8):2225-7. PubMed ID: 18668560
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
    Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
    JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.